DE vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Deere & Company and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Deere & Company · Industrials
$589.24
-29.6% upside to fair value
Grade D
High Quality
VS
Johnson & Johnson · Healthcare
$228.39
-20.6% upside to fair value
Grade D
High Quality
QuantHub Verdict
JNJ has more upside to fair value
(-20.6%).
JNJ trades at a lower forward P/E
(26.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DE |
JNJ |
| Current Price |
$589.24 |
$228.39 |
| Fair Value Estimate |
$414.61 |
$181.44 |
| Upside to Fair Value |
-29.6%
|
-20.6%
|
| Market Cap |
$159.1B |
$549.8B |
| Forward P/E |
33.3x
|
26.3x
|
| EV / EBITDA |
18.8x
|
17.4x
|
| Price / Sales |
3.4x
|
5.7x
|
| Price / FCF |
42.2x
|
30.9x
|
| Revenue Growth YoY |
+6.7%
|
+9.9%
|
| Gross Margin |
35.4%
|
69.1%
|
| Operating Margin |
18.4%
|
26.9%
|
| Return on Equity |
18.3%
|
26.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.37%
|
3.24%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Deere & Company is a leading global manufacturer of agricultural, construction, and forestry machinery with a durable competitive moat anchored by its number one market share in large agricultural equipment and a dense dealer network. The company benefits from embedded precision agriculture technology that widens its competitive gap, particularly in North America where it holds 40 to 60 percent m…
Johnson & Johnson is a leading global healthcare company focused on innovative medicine and MedTech following the Kenvue consumer spin-off. It benefits from a durable competitive moat with strong market positions in pharmaceuticals and medical devices, supported by a long-tenured management team and disciplined capital allocation. However, the stock is currently very expensive, trading approximat…
Accumulation Zones
| Metric |
DE |
JNJ |
| Zone Low |
$310.96 |
$136.08 |
| Zone High |
$352.42 |
$154.22 |
| In Buy Zone? |
No
|
No
|